Global Bronchial Spasms Treatment Market Report and Forecast 2024-2032

Global Bronchial Spasms Treatment Market Outlook

The rising prevalence of asthma drives the value of the bronchial spasms treatment market size. The number of asthma cases was nearly 306.09 million in 2023. The prevalence of the disease is likely to grow at a rate of 4.0% in the forecast period of 2024-2032. With this growth rate, the number of cases expected in 2032 is approximately 435.67 million.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Bronchial Spasms: Disease and Treatment Outlook

Bronchial spasms are among the most common pulmonary disorders. In bronchial spams, the muscles around the bronchial tubes contract or inflame and obstruct the airway flow. This leads to irregular or short breathing and, in extreme situations, can lead to death.

The most common symptoms of bronchial spasms include wheezing, pain in the chest, difficulty in breathing and coughing. The contraction and inflammation of bronchial muscles are due to the associated pulmonary disorders like emphysema, asthma, bronchitis, or chronic obstructive pulmonary disease (COPD). 

Bronchial spasms are likely to affect children, older adults, and people with weakened immune systems. People suffering from other allergies like food allergies or eczema are also expected to develop bronchial spasms.

Diagnosis and Therapeutic Interventions

Early diagnosis of bronchial spasms is important for proper therapeutic intervention. The diagnosis is done using tests like CT scans, chest X-rays, mucus testing or other imaging tests. Spirometry is an important diagnostic test used to measure the amount of air inhaled and exhaled through the lungs.

Treatment interventions for bronchial spasms depend on the pathophysiology and the severity of the disease. The effective treatment strategies are administering inhaled steroids, use of , and changes in lifestyle patterns.

According to the bronchial spasms treatment market research report, the market can be categorised into the following segments:

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Breakup by Diagnosis Type

• Imaging Test

• Spirometry Test

• Others

Market Breakup by Treatment Type

• Short-acting Bronchodilators
  • Levalbuterol (Xopenex, Xopenex HFA)
  • Albuterol (AccuNeb, Proventil HFA, ProAir HFA, Ventolin HFA)
• Long-acting Bronchodilators
  • Aclidinium (Tudorza)
  • Arformoterol (Brovana)
  • Formoterol (Foradil, Perforomist)
  • Glycopyrrolate (Seebri Neohaler)
  • Indacaterol (Arcapta)
  • Olodaterol (Striverdi Respimat)
  • Salmeterol (Serevent)
  • Tiotropium (Spiriva)
• Inhaled Steroids
  • Salbutamol
• Oral or Intravenous Steroids

Bronchial Spasms Treatment Market Breakup by Distribution Channel

• Hospitals

• Diagnostic Centres

• Clinics

• Others

Market Breakup by Region

• North America
  • United States of America
  • Canada
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
• Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Bronchial Spasms Treatment Market Scenario

The bronchial spasms treatment market is driven by the increasing prevalence and incidence of respiratory disorders like emphysema, asthma, chronic bronchitis, and chronic obstructive pulmonary disorder. In 2021, around 283 million people were diagnosed with asthma, which is why there is more demand for more air inhalers, facilitating market growth.

Technological advancements are one of the primary drivers attributing to the development of the market. Healthcare products are getting better and better with the rapidly evolving innovative technologies. For example, with the invention of smart inhalers, patients can poise their dosage and take it according to their suitability.

The additional factors supplementing the market growth include rising adoption of IoT devices, increasing geriatric population, and increased investments by the key players.

Short-Acting Bronchodilators Hold the Largest Share

Short-acting bronchodilators account for the largest share of the global market. This can be attributed to its immediate therapeutic effect in treating acute or chronic bronchial spasms.

North America is Anticipated to be the Dominant Regional Market

North America will hold a significant share of the bronchial spasms treatment market. This is due to the technological advancements, rising geriatric population, increasing awareness and more research and developmental activities.

Therapeutic Landscape

There are several treatment strategies for the management of bronchial spasms. Through diagnostic studies, the healthcare provider provides the best possible treatment. The treatment of bronchospasms is done with bronchodilators. The bronchodilators are administered through air inhalers, nebulisers, or tablet dosage forms.

Potent Remedies

The bronchodilator type is prescribed to assess the extremity of the situation. Short-acting bronchodilators are generally defined in case of immediate or rapid effects. This type of medication can open the blocked pathways within minutes. Some examples of these medications are Levalbuterol and Albuterol.

The long-acting bronchodilators take longer time to show their therapeutic effects but effectively reduces the risk of bronchospasms in the near future. Some long-acting bronchodilators are Aclidinium, Arformoterol, Formoterol, Glycopyrrolate, Indacaterol, Olodaterol, Salmeterol, and Tiotropium.

In case of severe or chronic bronchitis, inhaled steroids are incorporated as a therapeutic intervention. The steroids reduce the inflammation around the bronchial muscles. The oral and intravenous routes are the optimal administration routes for steroids.

Tremendous efforts of scientists, researchers, and healthcare professionals will lead to innovative therapies that will lay the foundation for next-generation technologies. 

Henceforth, all these novel treatments will help improve healthcare and the global economy. These new treatment strategies will majorly drive the growth of the global bronchial spasms treatment market in the forecast period.

Clinical Trial Landscape

With extensive research and development, novel treatment methods are being discovered, projected to boost the growth of the bronchial spasms treatment market. During the clinical trials, combination therapies proved excellent treatment sources due to their synergistic therapeutic action.

Novel Targeted Therapies and Programs

Incorporating two monotherapies, inhaled corticosteroids, and short-acting beta two agonists as a single combined therapy will provide dual therapeutic action. The corticosteroids help reduce inflammation in bronchial airways and potentiate short-acting bronchodilators' therapeutic response.  

In 2023, Pantherics Inc., a key player, received funds of USD 255,000 from the National Institutes of Health. This will facilitate the clinical trials for a novel bronchospasms drug that will be used to manage asthma and other pulmonary disorders.

The clinical trials are also done to increase patient awareness and adherence to the prescribed medication schedule. For example, in 2023, Boehringer Ingelheim Pharmaceuticals and HealthPrize conducted a program to educate chronic obstructive pulmonary disorder patients about medication adherence. 

Implementing technology in healthcare has already provided enormous benefits to human health. Researchers’ tremendous efforts have anticipated a rapid increase in the approvals for bronchial spasms therapies. Several ongoing clinical trials are emerging as a key driving factor for market growth and development.

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the bronchial spasms treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

• Novartis International AG

• GSK plc

• Merck & Co., Inc.

• AstraZeneca plc

• C. H. Boehringer Sohn Co. KG

• Teva Pharmaceutical Industries Ltd.

• Viatris Inc.

• Sunovion Pharmaceuticals Inc.

• Amphstar Pharmaceuticals, Inc.

• Pfizer, Inc.

Key Highlights of the Report